[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200301459B - Infusion of ciprofloxacin having reduced acid content and being stable in storage. - Google Patents

Infusion of ciprofloxacin having reduced acid content and being stable in storage.

Info

Publication number
ZA200301459B
ZA200301459B ZA200301459A ZA200301459A ZA200301459B ZA 200301459 B ZA200301459 B ZA 200301459B ZA 200301459 A ZA200301459 A ZA 200301459A ZA 200301459 A ZA200301459 A ZA 200301459A ZA 200301459 B ZA200301459 B ZA 200301459B
Authority
ZA
South Africa
Prior art keywords
ciprofloxacin
infusion
stable
storage
acid content
Prior art date
Application number
ZA200301459A
Other languages
English (en)
Inventor
Klaus Sommermeyer
Mueller Hans-Joerg Hniope Tilo
Bernd Eschenbach
Original Assignee
Fresenius Kabi De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi De Gmbh filed Critical Fresenius Kabi De Gmbh
Publication of ZA200301459B publication Critical patent/ZA200301459B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200301459A 2000-09-29 2003-02-24 Infusion of ciprofloxacin having reduced acid content and being stable in storage. ZA200301459B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10048510A DE10048510A1 (de) 2000-09-29 2000-09-29 Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt

Publications (1)

Publication Number Publication Date
ZA200301459B true ZA200301459B (en) 2003-08-27

Family

ID=7658237

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200301459A ZA200301459B (en) 2000-09-29 2003-02-24 Infusion of ciprofloxacin having reduced acid content and being stable in storage.

Country Status (17)

Country Link
US (1) US20040082593A1 (fr)
EP (1) EP1320368A1 (fr)
JP (1) JP2004509921A (fr)
KR (1) KR20030068541A (fr)
CN (1) CN1466457A (fr)
AU (1) AU2002214993A1 (fr)
BR (1) BR0114293A (fr)
CA (1) CA2420556A1 (fr)
DE (1) DE10048510A1 (fr)
HU (1) HUP0302256A2 (fr)
IL (1) IL154509A0 (fr)
MX (1) MXPA03002770A (fr)
NO (1) NO20031411D0 (fr)
PL (1) PL360597A1 (fr)
SK (1) SK3322003A3 (fr)
WO (1) WO2002026233A1 (fr)
ZA (1) ZA200301459B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3062786C (fr) 2010-07-09 2022-04-19 Janssen Vaccines & Prevention B.V. Anticorps anti-virus respiratoire syncytial (rsv) humain et procedes d'utilisation
WO2014174846A1 (fr) 2013-04-25 2014-10-30 杏林製薬株式会社 Composition pharmaceutique solide
JP5700740B1 (ja) 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
JP6018334B2 (ja) 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物
WO2016195020A1 (fr) 2015-06-02 2016-12-08 杏林製薬株式会社 Médicament aqueux
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
EP3305296A4 (fr) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. Formulation liquide aqueuse
CN114767627B (zh) * 2022-05-17 2024-05-31 广州南鑫药业有限公司 一种乳酸环丙沙星氯化钠注射液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
AU4201189A (en) * 1988-08-26 1990-03-23 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
DE10018781A1 (de) * 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Infusionslösungen des Ciprofloxacins mit verbesserter Lagerfähigkeit
DE10018783A1 (de) * 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt

Also Published As

Publication number Publication date
WO2002026233B1 (fr) 2002-07-04
CN1466457A (zh) 2004-01-07
IL154509A0 (en) 2003-09-17
KR20030068541A (ko) 2003-08-21
JP2004509921A (ja) 2004-04-02
AU2002214993A1 (en) 2002-04-08
BR0114293A (pt) 2003-07-29
MXPA03002770A (es) 2004-12-13
CA2420556A1 (fr) 2003-02-25
PL360597A1 (en) 2004-09-20
NO20031411D0 (no) 2003-03-27
DE10048510A1 (de) 2002-05-16
WO2002026233A1 (fr) 2002-04-04
EP1320368A1 (fr) 2003-06-25
SK3322003A3 (en) 2003-07-01
US20040082593A1 (en) 2004-04-29
HUP0302256A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
GB0005839D0 (en) Storage and delivery of micro-organisms
WO2000061192A3 (fr) Methodes et compositions pour le traitement de la pancreatite
MXPA02005797A (es) Metodos y dispositivos electroquimicos para su uso en la determinacion de concentraciones de analitos con hematocrito corregido.
AU2002332580A1 (en) Cell storage and delivery system
WO2004052401A3 (fr) Compositions et methodes d'administration d'agents pharmacologiques
MX295630B (es) Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
HK1039076A1 (en) Game system and computer readable storage medium
IL144508A0 (en) Compositions and methods for use in targeting vascular destruction
AU2002340415A1 (en) Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care
AU2002254942A1 (en) Paracetamol solutions which are stable in storage and ready for infusion
WO2002002093A3 (fr) Nouvelles polytherapies aux antifolates
HUP0202329A2 (en) Pharmaceutical composition in unit form containing acetylsalycilic acid and clopidogrel hydrogenosulphate
AU2001273941A1 (en) Ciprofloxacin infusion solutions having a good storage stability
HUP0200827A3 (en) Vascular endothelial cell growth factor variants and uses thereof
ZA200301459B (en) Infusion of ciprofloxacin having reduced acid content and being stable in storage.
WO2002032397A8 (fr) Mise en oeuvre d'un traitement electrique pour l'administration de medicaments et l'encapsulation de cellules
ZA200300704B (en) Storage stable tretinoin and 4-hydroxy anisole containing topical composition.
AU2001282317A1 (en) Capture, storage and retrieval of markup elements
GB9927810D0 (en) Hydrate storage and transportation
AU2003278673A8 (en) Container with acid diffusion barrier and use thereof
AU2002226986A1 (en) In vivo delivery methods and compositions
AU2001260198A1 (en) Ciprofloxacin infusion solutions with improved storage life
AU2001260291A1 (en) Combination of cerivastatin with ace inhibitors and the use thereof in medicaments
AU4851601A (en) Storage and transport vessel
AU2001269106A1 (en) Novel alpha expressed in heart and testis